See more : Yeou Yih Steel Co., Ltd. (9962.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of CHO Pharma, Inc. (6586.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CHO Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Manaksia Steels Limited (MANAKSTELTD.BO) Income Statement Analysis – Financial Results
- Solvay Bank Corp. (SOBS) Income Statement Analysis – Financial Results
- Brighten Optix Corporation (6747.TWO) Income Statement Analysis – Financial Results
- Solstice Minerals Limited (SLS.AX) Income Statement Analysis – Financial Results
- Cerrado Gold Inc. (CRDOF) Income Statement Analysis – Financial Results
CHO Pharma, Inc. (6586.TWO)
About CHO Pharma, Inc.
CHO Pharma, Inc., a biopharmaceutical company, develops and commercializes therapeutic and diagnostic products for the unmet clinical needs. It is developing homogeneous antibody drugs, such as CHO-H01, CHO-H02, and CHO-A04, a humanized monoclonal antibody for cancer; CHO-H03, a homogeneous antibody drug for autoimmune diseases; CHO-S05 dual-effect anti-flu drugs; and CHO-V08 for Klebsiella pneumonia. The company was founded in 2012 and is based in Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 60.00K | 3.57M | 138.00K | 297.00K |
| Cost of Revenue | 28.28M | 1.00K | 211.00K | 71.00K | 119.00K |
| Gross Profit | -28.28M | 59.00K | 3.36M | 67.00K | 178.00K |
| Gross Profit Ratio | 0.00% | 98.33% | 94.09% | 48.55% | 59.93% |
| Research & Development | 239.39M | 326.10M | 193.51M | 287.88M | 344.63M |
| General & Administrative | 21.52M | 24.86M | 20.35M | 21.74M | 24.71M |
| Selling & Marketing | 8.10M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.61M | 24.86M | 20.35M | 21.74M | 24.71M |
| Other Expenses | 0.00 | 5.75M | -319.00K | 5.38M | 0.00 |
| Operating Expenses | 269.00M | 350.96M | 213.85M | 309.62M | 370.21M |
| Cost & Expenses | 269.00M | 350.96M | 214.06M | 309.69M | 370.33M |
| Interest Income | 16.24M | 7.05M | 5.46M | 8.11M | 12.06M |
| Interest Expense | 77.00K | 301.00K | 576.00K | 775.00K | 401.00K |
| Depreciation & Amortization | 28.28M | 39.85M | 39.08M | 41.24M | 29.22M |
| EBITDA | -277.73M | -302.28M | -170.16M | -258.93M | -323.92M |
| EBITDA Ratio | 0.00% | -497,070.00% | -4,657.31% | -184,654.35% | -114,459.26% |
| Operating Income | -269.00M | -338.09M | -205.35M | -296.06M | -369.16M |
| Operating Income Ratio | 0.00% | -563,486.67% | -5,752.07% | -214,539.13% | -124,297.31% |
| Total Other Income/Expenses | -37.09M | 12.51M | 4.57M | 12.72M | 10.79M |
| Income Before Tax | -306.09M | -338.39M | -205.93M | -296.84M | -358.37M |
| Income Before Tax Ratio | 0.00% | -563,988.33% | -5,768.21% | -215,100.72% | -120,663.97% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -306.09M | -338.39M | -205.93M | -296.84M | -358.37M |
| Net Income Ratio | 0.00% | -563,988.33% | -5,768.21% | -215,100.72% | -120,663.97% |
| EPS | -1.60 | -1.84 | -1.12 | -1.62 | -1.96 |
| EPS Diluted | -1.60 | -1.84 | -1.12 | -1.62 | -1.96 |
| Weighted Avg Shares Out | 191.32M | 183.96M | 183.89M | 183.67M | 183.02M |
| Weighted Avg Shares Out (Dil) | 191.32M | 183.96M | 183.89M | 183.67M | 183.02M |
Source: https://incomestatements.info
Category: Stock Reports